PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.

Themis secured £3 million from Innovate UK for its Chikungunya vaccine project.

An American university and a group of wealthy libertarians, including Peter Thiel, are backing the offshore testing of an experimental herpes vaccine.

Soligenix just got another $2.5 million awarded from an NIAID contract to support manufacturing of a heat-stable ricin vaccine for future studies.

HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.

Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.

Meissa Vaccines, a JLABS resident startup, has financial backing from the NIH and a VC firm to help advance its RSV vaccine candidate.

Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.

J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.

On the heels of new genital herpes data, one analyst believes things may get a whole lot better at Genocea.